<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929719</url>
  </required_header>
  <id_info>
    <org_study_id>DPSG 1518, 1216</org_study_id>
    <nct_id>NCT02929719</nct_id>
  </id_info>
  <brief_title>Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Test Gel, 5% to ACZONE Gel, 5% and Both Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic equivalence and safety study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the therapeutic equivalence and safety of Test formulation and marketed Reference
      Listed Drug (RLD).

      To demonstrate the superiority of efficacy of the Test and Reference products over the
      placebo control in the treatment.

      To compare the safety of Test, Reference and Placebo treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory lesion count</measure>
    <time_frame>baseline to week 12 (study day 84)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in non-inflammatory lesion count</measure>
    <time_frame>baseline to week 12 (study day 84)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1134</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Test Gel 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical, twice daily on the face for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACZONE Gel 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical, twice daily on the face for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical, twice daily on the face for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test.</intervention_name>
    <description>gel</description>
    <arm_group_label>Test Gel 5%</arm_group_label>
    <other_name>dapsone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aczone Gel 5%</intervention_name>
    <description>gel</description>
    <arm_group_label>ACZONE Gel 5%</arm_group_label>
    <other_name>dapsone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>gel</description>
    <arm_group_label>Placebo Gel</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis
             of acne vulgaris

          -  Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3,
             or 4 as per the Investigator's Global Assessment (IGA) (per Table 1 below)

        Exclusion Criteria:

          -  Female Subjects who are pregnant, nursing or planning to become pregnant during study
             participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catawba Research</last_name>
    <role>Study Chair</role>
    <affiliation>http://catawbaresearch.com/contact/</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

